US › Healthcare

Serina Therapeutics Inc (SER)

US · Healthcare · Biotechnology

$2.14+3.88%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-6.9M

Profit YoY

-43.3%

EPS

$-0.53

EPS estimate

$-0.44

EPS came in at -0.53 against a street estimate of -0.44 — a miss of 20.5%.

Key statistics

Market cap

$30.0M

Forward P/E

0.0

P/B

2.36

Book value

$0.85

EPS (TTM)

$-2.00

52-week high

$7.92

52-week low

$1.22

50-day MA

$1.96

200-day MA

$2.54

Beta

0.03

Analyst view

Analysts rate Serina Therapeutics Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $9.50.

Shareholding

Insiders

85.96%

Institutions

9.84%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Serina Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.